GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones released from specialized entero-endocrine cells in the intestinal mucosa in response to nutrient intake.
“Among the gut peptides are GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), incretin hormones released from specialized entero-endocrine cells in the intestinal mucosa stimulated by nutrient intake (5).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [5]
The citation lists haven’t been fetched yet
References 10 · Cited by 22
- Authors
- Nauck, M. A., & Meier, J. J.
- Affiliations
- University Hospitals of the Ruhr-University of Bochum (DE)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2016-12
- Volume
- 4
- Issue
- 12
- Pages
- 963-964
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2519154616
- Cited by
- 22
- References
- 10
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 3 · 2019: 3 · 2018: 3 · 2017: 4
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, SGLT2 inhibitors, exenatide, dapagliflozin, type 2 diabetes, combination therapy, HbA1c, cardiovascular risk factors, drug safety, antidiabetic drugs
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Sodium-Glucose Transporter 2, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
